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Abstract
Because posttraumatic stress disorder (PTSD) is a highly debilitating condition, prevention is an important research topic.
This article reviews possible prevention approaches that involve the administration of drugs before the traumatic event
takes place. The considered approaches include drugs that address the sympathetic nervous system, drugs that interfere
with the hypothalamic-pituitary-adrenal (HPA) axis, narcotics and other psychoactive drugs, as well as modulators of
protein synthesis. Furthermore, some thoughts on potential ethical implications of the use of drugs for the primary
prevention of PTDS are presented. While there are many barriers to overcome in this field of study, this paper concludes
with a call for additional research, as there are currently no approaches that are well-suited for regular use.
Keywords: Posttraumatic stress disorder, PTSD, Prevention, Pre-treatment, Propranolol, Prazosin, Ketamine, Morphine,
Anisomycin, Osanetant
Introduction
Confrontation with extremely violent or painful events
can cause a mental condition known as posttraumatic
stress disorder (PTSD). This condition is highly debili-
tating as its symptoms – exceptionally vivid intrusive
recollections, a sense of reliving the trauma, amnesia for
parts of the traumatic event, and hyperreactivity to
trauma reminders – severely interfere with the daily lives
of the persons affected, as well as with their social envir-
onment [1]. Prevention of such a condition is thus
highly desirable. Current approaches to PTSD preven-
tion can be subdivided into primary prevention (before
the traumatic event, including prevention of the event
itself ), secondary prevention (between the traumatic
event and the development of PTSD), and tertiary pre-
vention (after first symptoms of PTSD become apparent)
[2]. This paper focuses on primary prevention by apply-
ing drugs before a traumatic event takes place. Addition-
ally, selected literature on secondary pharmacological
prevention is reviewed to derive evidence for potential
primary prevention applications of additional drugs (see
also [3]). Other forms of primary prevention, such as
anticipative psychological interventions or measures to
protect susceptible persons from being involved in
potentially traumatic events, are beyond the scope of
this paper.
Primary pharmacological prevention of PTSD has little
relevance for average citizens, as traumatic events (e.g.,
severe accidents, having a child with a serious illness or
events of sexualized violence) are comparatively rare and
unpredictable. Accordingly, the lifetime prevalence of
PTSD for the general population in six countries moni-
tored varies, from just over 2 % in Spain and Italy, to
7.8 % in the USA and 8.8 % in Northern Ireland (France
and Sweden are between those extremes). PTSD preva-
lence seems to be significantly influenced by the impact
of armed conflicts on the population (e.g., World Wars I
and II or the “troubles” in Northern Ireland) [4].
However, in the case of military personnel, experiences
of extreme violence may be anticipated under certain
conditions, e.g., when being deployed in combat zones.
Correspondingly, PTSD is quite common among mili-
tary veterans. A recent report of the US Department of
Veterans Affairs states that between 2002 and 2012 ap-
proximately 257,000 veterans from Iraq and Afghanistan
have been diagnosed with PTSD, out of approximately
1.63 million veterans from post-9/11 wars (16 %) [5, 6].
This is well in line with a previous comparative analysis
that indicated that combat-related PTSD afflicts 4–17 %
of US Iraq War veterans and 3–6 % of returning UK
Iraq War veterans [7]. Furthermore, there is some
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evidence that deployed military health care personnel
have an even higher risk of developing PTSD symp-
toms than other military staff [8]. PTSD thus repre-
sents a huge medical, social and financial problem to
nations at war.
Pharmacological options
Both psychological and physiological research indicates
that the influence of stress on memory formation is a
key point in the development of PTSD [1]. The main
pharmacological options for primary PTSD prevention
are thus related to stress hormones and their respective
receptors. Generally speaking, poor memory formation
seems to be beneficial for long-term mental health after
traumatic events, while interventions that enhance
memory formation (like short “de-briefings” after the
traumatic event) can even raise the risk of PTSD [9].
Several biochemical systems are involved in handling
acute stress, including the hypothalamic-pituitary-
adrenal (HPA) axis, the autonomic nerve system (espe-
cially the sympathetic nerve system) and interactions be-
tween the pre-frontal cortex (PFC), hippocampus and
amygdala. To further complicate matters, these systems
show complex interdependencies. Furthermore, their
roles in PTSD formation change over time between the
traumatic event and the development of symptoms [10].
An overview of the pharmacological options for inter-
vention is given in this section, roughly sorted by the
biochemical systems addressed.
Drugs targeting the sympathetic nerve system
The autonomic nerve system encompasses all nervous
sub-systems that work beyond direct conscious control.
It is subdivided into the sympathetic nervous system
(mainly associated with activity and fear), the para-
sympathetic nervous system (mainly associated with rest
and relaxation), and the enteric nervous system (mainly
controlling the gastrointestinal system). The main trans
mitters associated with the sympathetic nerve system are
acetylcholine, nor-adrenaline (norepinephrine) and adren-
aline (epinephrine). While nor-adrenaline is physiologic-
ally short-lived and acts primarily as a short-distance
messenger substance between nerve cells (i.e., a neuro-
transmitter), adrenaline has more hormone-like attributes
in that it influences processes at a farther distance from
the point of release.
The release of large amounts of adrenaline from the
medulla of the adrenal gland leads to a “fight-or-flight”
state, characterized by highly focused attention and the
provision of energy to skeletal muscles. Beta-blockers
inhibit the binding of adrenaline and nor-adrenaline to
certain types of receptors and thus suppress the physio-
logical and psychological effects of these stress hor-
mones. Several dozens of different beta-blockers are
currently marketed as drugs for a variety of diseases,
especially hypertension and coronary artery disease
(CAD). A typical example is propranolol, which was
developed by Imperial Chemical Industries (ICI) in
the 1960s as an anti-hypertensive. Although propranolol
has a certain toxic potential, small doses are usually
well-tolerated. The most dangerous undesired effect
of low single doses of propranolol is triggering bron-
chial constriction in susceptible persons, e.g., asth-
matics. Furthermore, existing heart conditions may be
worsened [11]. Compared with other beta-blockers,
propranolol is able to easily pass the blood–brain bar-
rier [12]. This may be desirable in the context of
PTSD prevention, as it is yet unclear whether the
effect of adrenaline on memory consolidation acts
both through direct action in the brain and through
nervous system activity induced by binding to beta-
adrenergic receptors in the periphery [13], or if only
activity in the brain is of relevance [14].
The evidence concerning the effectiveness of propran-
olol in preventing PTSD is ambiguous. Several small
studies on injured patients showed little or no effect of
propranolol on the development of PTSD if given in the
context of intensive care (secondary prevention). These
disappointing observations, which contradict studies in
animal models and pre-clinical experiments with healthy
volunteers, may be attributed to three reasons: a. in the
situations studied, there was a time lag between the
trauma and the administration of propranolol, with the
shortest gap being 2 h but more typically application of
the drug began 4 to 20 h after the event (at which time
crucial memory processes might already have taken
place); b. the traumata of the patients tested were not
sufficiently severe to spark PTSD (as recruiting heavily
traumatized patients in an emergency department is
nearly impossible); and c. the doses applied were too low
to have an influence on memory processing [15]. How-
ever, in the case of primary prevention, the time lag
issue is of no relevance, as the drug would already be
present at the time of the event.
Another pressing question, especially from an ethical
and legal point of view, is whether beta-blockers really
inhibit memory formation (i.e., create a “clean slate”) or
if they just help to control an emotional over-reaction to
the trauma, leaving declarative memory formation intact.
While there has been extensive research on the effect of
propranolol on memory reconsolidation, which is a key
factor in PTSD therapy, studies on how memory
formation is influenced by propranolol in humans are
scarce and inconsistent [16]. A landmark study con-
ducted in 1994 with a small number of healthy volun-
teers indicated that pre-treatment with propranolol
eliminates the positive effect on memory that an
emotionally arousing story (accompanied by a slide
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show) has over an emotionally neutral account. This effect
is not attributable to sedation or impaired attention, as
no effect of propranolol was evident in test persons
that were confronted with the neutral story only. No
change in the subjective emotional reactions to the
story by propranolol was observed immediately after
viewing the slides. The effects of propranolol are thus
not attributable to reduced subjective emotional re-
sponsiveness [17]. These results suggest that the
formation of declarative memory is only brought back
to a neutral level by administering propranolol. Some
authors have suggested that propranolol might even
enhance factual memory of traumatic events, as the
strong perception of remembering highly emotional
events does not necessarily correlate with realistic,
detailed and accurate memory [18]. No evidence for
suppressing memory consolidation below the “neutral”
level by applying beta-blockers as primary preventives
has been found in the literature.
Overall, it can be concluded that beta-blockers might
be an option for primary prevention of PTSD from a
pharmacological point of view. However, determining
who should receive drugs, which drugs to administer,
and the appropriate dosage would nevertheless still
require substantial research efforts before any broad
application could be envisaged.
Alpha-blockers have a mechanism of action similar
to that of beta-blockers, but alpha blockers bind to a
different type of receptors. A representative of this
class of drugs is prazosin, which was first marketed
as an anti-hypertensive by Pfizer in 1969. Since the
1990s, low doses of prazosin have been used to treat
PTSD symptoms, especially sleep disturbances (like
distressed awakenings) and trauma-related nightmares
[19, 20]. The therapeutic effects of prazosin are usu-
ally attributed to blocking of alarm-related cognitive
mechanisms mediated by nor-adrenaline (norepineph-
rine) in the brain [21].
There are considerably less studies on the effects of
alpha-blockers on memory formation than for beta-
blockers. While a study in chickens hinted that alpha-
blockers might antagonize the negative effects of stress
on memory formation [22], a study on rats indicated
that prazosin might be useful in the primary prevention
of PTSD by reducing the formation of traumatic mem-
ory [23]. The potential of alpha-blockers for PTSD pre-
vention in humans is practically unknown [20].
While sympatholytic drugs (alpha- and beta-blockers)
do not usually impair mental functions, an inherent
drawback is their down-regulating activity on the cardio-
vascular system. While this is the desired effect when
treating hypertension, it might lead to reduced peak
performance in physically demanding situations, such as
in combat or in emergency operations.
Drugs interfering with the hypothalamic-pituitary-adrenal
(HPA) axis
The role of corticosteroids in the development of PTSD
is less straightforward than that of adrenergic transmit-
ters and the sympathetic system. While experiments in
animal models suggest that interventions that reduce the
effect of glucocorticoids (e.g., blockade of glucocorticoid
receptors) facilitate stress resilience, it has also been re-
ported that individuals with lower peritraumatic cortisol
levels have an increased likelihood of developing PTSD.
This may be due to the fact that glucocorticoids play a
role in the termination of the sympathetic stress re-
sponse. Inhibiting parts of the hypothalamic-pituitary-
adrenal (HPA) axis may thus increase the negative ef-
fects of adrenaline and nor-adrenaline in the develop-
ment of PTSD [10].
In 2001, Schelling et al. published a study on the effect
of cortisol administration to septic shock patients in an
intensive care unit. This study showed that significantly
fewer patients that had received cortisol in doses close
to those physiologically found in persons under extreme
stress had developed PTSD (1 of 9, compared with 7 of
11 in the control group). Interestingly, no effect of the
treatment on the number of categories of traumatic
memories could be established. Although the study was
methodologically sound, the very ill patients received
co-medication, including nor-adrenaline to combat the
shock, the benzodiazepine midazolam, as well as the
opioid fentanyl for sedation. All of these substances po-
tentially influenced the development of PTSD. While the
applied doses of midazolam and fentanyl are not known,
nor-adrenaline was given for a significantly shorter time
and thus in significantly lower doses to the patients
of the cortisol group [24]. The findings of this study
are valuable but somewhat difficult to interpret con-
cerning the effects of the individual drugs on PTSD
formation [25].
In a more controlled study in rats, glucocorticoids
were administered immediately after a traumatic event.
The results showed that high doses of corticoids
prevented the formation of PTSD-like behavior, while
low doses increased vulnerability to the trauma cue
compared to placebo. From additional memory tests, the
authors concluded that high doses of corticoids disrupt
memory consolidation, which is the conversion of short-
term memory to long-term memory, while low doses of
corticoids facilitate this process [25].
In light of these exemplary studies, the findings of
McCleery et al. of 2004 are still valid today: “Stress-level
cortisol treatment has the theoretical advantage of
correcting a possible abnormality in more vulnerable
trauma victims, while not abolishing a well-functioning
physiological defence mechanism in those more resilient
individuals (…) who would recover without intervention.
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However, given the uncertainties about the status of the
HPA axis in PTSD patients and the fact that acute corti-
sol administration has been found to enhance emotional
memory, this strategy too cannot be regarded as being
without risk of harm” [1].
Other drugs
There are some indications that opiates such as mor-
phine may reduce the likelihood of PTSD development
if given directly after a traumatic event, but there is still
little information about this effect [10]. The most
important study on opiates is a ex post evaluation of
medical records of 696 injured US military personnel
that were given morphine shortly (1 h or less for 71 % of
patients) after the traumatic event. These soldiers devel-
oped PTSD symptoms significantly less often than those
in the control group that had not received opiates, even
when other factors that might influence the outcome
were taken into account [26]. Nevertheless, the pharma-
cological effects of opiates (e.g., sedation and disorienta-
tion) make them ill-suited for primary prevention.
An ex post evaluation of military personnel that had
been treated for severe burns revealed that those patients
who had received the dissociative anesthetic ketamine
during surgery had significantly lower rates of PTSD than
those who had not, although their injuries had been more
severe than those of the control group. In this study, no
correlation between PTSD and morphine equivalent units
during operations was observed [27]. Again, as in opioids,
the pharmacological effects of ketamine (e.g., hallucina-
tions and psychomotor retardation) make it unsuitable for
primary prevention.
Although antidepressants are the most commonly
used drugs to treat the symptoms of PTSD, the evidence
for possible secondary or even primary preventive effects
is scarce [28].
Experiments on benzodiazepines, a class of drugs that
may cause anterograde amnesia, have shown that they
have no preventive effect on PTSD. Their calming ef-
fects may even facilitate memory formation in traumatic
events and thus foster the development of PTSD symptoms
[10, 28]. A recent meta-analysis found that benzodiazepines
influence the symptoms of PTSD in such a negative way
that the authors conclude that benzodiazepines should be
considered relatively contraindicated for patients with
PTSD or for those who have recently experienced trauma
[29]. Nevertheless, the neurotransmitter system addressed
by benzodiazepines (γ-amino butyric acid; GABA) should
not be completely ruled out as a potential target for PTSD
prevention [3].
It has been hypothesized that the conversion of labile
short-term memory into enduring long-term memory
requires the de novo synthesis of proteins. In the context
of this theory, rats were injected with anisomycin, a
protein synthesis inhibitor, immediately before or after a
traumatic event. An assessment of several parameters re-
vealed that the treated rats showed less PTSD-related
behavior than did untreated rats after the same stressful
event. No other behavioral differences between treated
and untreated rats were observed [30]. In this context, it
is worth noting that alternative mechanisms of protein
synthesis inhibitors affecting memory consolidation, e.g.,
by triggering neurotransmitter release, have been pro-
posed [31]. Again, experiments with protein synthesis
inhibitors such as anisomycin or cycloheximide are still
far away from any safe application in humans, although
some of these substances have previously been used as
antibiotics.
In 2014, osanetant was proposed as a potential drug
for the secondary prevention of PTSD. This drug, origin-
ally developed as a treatment for schizophrenia but never
brought to the market, antagonizes the effect of a certain
neuropeptide on the neurokinin 3 receptor (NK3R). It was
shown that its application lowers the consolidation of fear
memories in mice [32]. As osanetant is safe and well-
tolerated in humans, it might also be of use for the
primary prevention of PTSD.
Thoughts on ethical implications
As primary pharmacological prevention of PTSD touches
issues of traumatic events and possibly even questions of
life and death, ethical issues have to be considered, both in
the application of pre-medication and, maybe even more,
in the study of such options. Some thoughts on this are
given in this section.
Concerning the application of drugs to “blue forces”, a
decision balancing risks and benefits has to be taken. In
this, giving drugs for the primary prevention of PTSD is
very comparable to the ethical issues associated with
vaccination (against natural and man-made infective
agents) and “pre-treatment” against unconventional
weapons (e.g., pyridostigmine against nerve agents). These
considerations will strongly depend on the beneficial and
adverse effects of the drugs used, and on the conditions of
their application.
A further question must be asked: Will reducing the
risk of developing PTSD after a traumatic event alter the
disposition of commanders to expose their personnel to
dangerous situations? In theory, this could be a possible
effect. Nevertheless, it seems that the risk of personnel
developing PTSD has little influence on tactical deci-
sions today: The risk of developing PTSD is relatively
“far away” compared to the more manifest risks of
physical harm. However, lowering the risk of PTSD
through drugs might alter strategic decisions, e.g.,
personnel rotation. This deserves further attention.
Concerning the application of chemical substances in
war situations, international treaties such as the Biological
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Weapons Convention need to be taken into consideration.
Nevertheless, these conventions address the application of
pharmacological agents to the enemy. As pre-medication
is given to “blue” personnel, the rules of these conventions
are not applicable. Furthermore, in the case of the Bio-
logical Weapons Convention, prophylactic and protective
purposes are explicitly allowed.
Research on primary pharmacological prevention of
PTSD is a field struck with massive ethical issues. Given
the severity of PTSD, animal models can be acceptable
under controlled conditions. Nevertheless, PTSD is a
complex psychological state and the comparability of
such states in animal models and in humans needs to be
carefully analyzed to avoid wrong conclusions. In any
case, while studies in animals can give valuable clues
concerning pharmacological options, they are just a first
step in the development of novel therapies that must be
followed up by studies with human volunteers. Such
studies feature the most challenging ethical issues in this
field of research: deliberately confronting volunteers with
events that could lead to the development of PTSD is
not an acceptable option. However, recruiting volunteers
that have recently experienced a traumatic event is also
ethically challenging. Furthermore, as the recruitment
takes place after the event, it is by definition too late
to administer drugs for primary prevention. An alter-
native study design could involve the pre-medication
of personnel that might be confronted with traumatic
situations due to their professions. This resolves the prob-
lem of deliberately applying traumatic stimuli to healthy
volunteers but brings up two new issues: a. although the
likelihood of traumatic events is raised for certain profes-
sions, the time of occurrence of such events is not known.
This might lead to the necessity to expose healthy
volunteers to adverse drug effects for a long time, with
only a limited chance of positive impacts on the persons
involved; and b. some of the experimental drugs can lead
to diminished physical and psychological performance.
This might raise the risk of occupational accidents for the
volunteers (and the persons they interact with), again
without direct beneficial effects for the persons involved.
Conclusions
There is a clear indication that pharmacological second-
ary prevention is most effective when started early after
the traumatic event. Therefore, it can be speculated that
applying the same drugs before a trauma might increase
effectiveness. Nevertheless, two of the most promising
substances used for secondary prevention (morphine
and ketamine) have pharmacological profiles that ex-
clude their use in primary prevention, as sedation and
psychotropic effects are undesirable under dangerous
circumstances. Presently, sympatholytic drugs (alpha-
and beta-blockers) seem to have the highest potential to
be used as primary preventive drugs for PTSD, although
they also have the potential both to do medical harm in
average people and to deteriorate mission critical per-
formance. While several other pharmacological options
have been proposed, evidence for even a preliminary
assessment is either insufficient or inconsistent in most
cases (see Table 1).
The main hypothesis about how the substances dis-
cussed in this paper prevent PTSD is by blocking the
formation of long-lasting traumatic memories of an event.
Apart from the pharmacological obstacles to use such
“memory blockers” in primary prevention, it is also disput-
able whether blocking the formation of memory during
missions is desirable from a tactical point of view, as indi-
vidual and organizational learning from past deployments
constitutes a key element of military planning. There is
thus a dire need to research alternative mechanisms of
primary prevention.
Table 1 Tentative assessment of potential drugs for primary PTSD prevention






Potential effectiveness for primary
PTSD prevention
Beta-blockers propranolol yes some no yes
Alpha-blockers prazosin yes some no unknown
Corticosteroids cortisol no no no contradictory evidence
Opiates morphine no yes yes yes, but strong performance impairment
Anesthetics ketamine no yes yes yes, but strong performance impairment
Antidepressants several sub-classes yes no some unknown
Sedatives benzodiazepines yes no yes probably none
Protein synthesis
inhibitors
anisomycin, cycloheximide no some no yes, based on animal models
NK3-antagonists osanetant no unknown unknown unknown
Undesirable effects are usually dose dependent. In this table, typical therapeutic doses are the basis for the estimation of undesirable effects in healthy adults
The assessment of the potential effectiveness for primary PTSD prevention is a tentative evaluation based on currently available data
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Studies with volunteers in the area of primary pharma-
cological PTSD prevention tend to be burdened by
massive ethical problems. A possible direction for
further clinical research would be the ex post evaluation
of the clinical records of persons that have experienced
traumatic events while being under the influence of
drugs (e.g., beta-blockers or antidepressants) for medical
reasons unrelated to the trauma. Such research would
have to overcome several obstacles: a. incomplete medical
records (military records that tend to be rather complete
would be useless in this context, as military personnel
suffering from conditions that require medication with
such drugs would not be sent on dangerous missions); b. a
large diversity of the study group, including varying
post-traumatic pharmacotherapy; and c. difficult data
acquisition concerning the psychological outcome several
months or even years after the traumatic event. Neverthe-
less, such a study could reveal new and unexpected
options for pharmacological primary prevention of PTSD.
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